Rapport Therapeutics, Inc.
NGM: RAPPLive Quote
📈 ZcoreAI Score
Our AI model analyzes Rapport Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get RAPP Z-Score →About Rapport Therapeutics, Inc.
Healthcare
Biotechnology
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
📊 Fundamental Analysis
Rapport Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -28.2%, which indicates that capital utilization is currently under pressure.
At a current price of $34.17, RAPP currently sits at the 77th percentile of its 52-week range (Range: $7.73 - $42.27).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
Key Financials
Market Cap
$1.63B
Trailing P/E
--
Forward P/E
-8.74
Beta (5Y)
--
52W High
$42.27
52W Low
$7.73
Avg Volume
324K
Day High
Day Low